Clinical trials: Immunocompromised Patients, open to volunteers
Community Acquired Pneumonia (CAP)
ItAlian ReGistry Of pNeumoniA in immUnocompromised paTients (ARGONAUT)
This multicentric, prospective study aims at: evaluating the prevalence, etiology, characteristics, and 1one-year outcomes of immunocompromised patients hospitalized for Community-Acquired Pneumonia (CAP); conducting biochemical…
- Trial name
- ARGONAUT (NCT06755814)
- Where
- Italy
- Volunteers
- 1,298 people
- Sponsor
- Societa Italiana di Pneumologia
SARS-CoV-2 Infection
T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients
This is an open label, phase I dose-escalation study to evaluate the safety of coronavirus-specific T cell (CST) therapy for prevention of SARS-CoV-2 infection in immunocompromised patients following hematopoietic stem cell…
- Trial name
- TONI (NCT05141058)
- Testing
- Coronavirus-specific T cell (CST)
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Children's National Research Institute
Pneumocystis, Immunocompromised Patients
Optimizing the Diagnosis of Pneumocystis in Immunocompromised Patients
Evaluate new diagnostic methods using qPCR on non-invasive samples, compared with reference techniques for the positive diagnosis of pneumocystis (PcP) in immunocompromised patients
- Trial name
- OPTIJIROVEC (NCT06890078)
- Testing
- Biological sampling
- Where
- 4 sites in France
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
RSV Infection
RSV Vaccination in Immunocompromised Patients.
Respiratory syncytial Virus (RSV) causes respiratory infections worldwide and typically presents with a seasonal pattern peaking in autumn/winter in temperate climate zones.
- Trial name
- NCT06597916
- Testing
- Arexvy powder and suspension for injection
- Where
- Austria
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Infection, Infections, Bacterial
Microbial Cell-free Metagenomic Sequencing for Suspected Infections in Adult Immunocompromised Outpatients
This clinical trial is designed to evaluate if adding the Karius Spectrum™ plasma test to usual care diagnostic tests, compared to usual care testing alone, among immunocompromised participants presenting with suspected infection…
- Conditions
- Infection, Infections, Bacterial, Infections, Fungal, Infection Viral
- Trial name
- OPTIMUM (NCT07110636)
- Testing
- Metagenomic plasma-based test for agnostic pathogen detection
- Where
- 6 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Karius, Inc.
Human Papillomavirus
Natural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune)
Background: Most symptoms of human papillomaviruses (HPV) infection, do not cause serious health problems, but some do. As HPV can cause uncontrolled growth of infected cells, some people can develop benign skin lesions, larger…
- Trial name
- NCT05026138
- Where
- United States
- Volunteers
- 850 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Fever, Cancer
Remote Temperature Monitoring of Patients At Risk for Developing Fever
The purpose of this program is to evaluate remote temperature monitoring in cancer patients at risk of fever and infection due to chemotherapy treatment.
- Conditions
- Fever, Cancer, Remote Patient Monitoring
- Trial name
- NCT06752512
- Testing
- Remote Patient Monitoring
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- AION Biosystems
Tuberculosis
Immunocompetent Versus Immunocompromised Tuberculosis (TB) Patients
Tuberculosis (TB) is caused by Mycobacterium tuberculosis and is one of the top 10 causes of mortality worldwide. It is estimated that in 2017, 10 million people were infected with TB, and 1.6 million died from the disease…
- Trial name
- NCT06709157
- Testing
- P24 antigens and antibody, zeihl - Nelsen stain, culture on Lowenstein jensen media
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Sohag University
COVID-19 Infection
A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
This is a Phase 3, randomized, actively controlled, double-blinded, double-dummy, superiority study to evaluate the efficacy and safety of ibuzatrelvir alone and in combination with remdesivir IV compared to remdesivir IV alone…
- Trial name
- NCT07013474
- Testing
- ibuzatrelvir, remdesivir
- Where
- 159 sites in United States, Argentina and 16 more
- Volunteers
- 300 people
- Sponsor
- Pfizer
Rabies Exposure, Immunocompromised
Clinical Study on Immunogenicity and Safety of Lyophilized Vero Cell-Derived Human Rabies Vaccine in Special Populations
This study adopts a parallel-controlled design and includes a study group and a control group. The study group will enroll 150 special population participants (including non-HIV-related immunocompromised individuals, patients…
- Conditions
- Rabies Exposure, Immunocompromised, Chronic Disease
- Trial name
- NCT07120464
- Testing
- Observation Only
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Liaoning Chengda Biotechnology CO., LTD
Viral Infection, Viral Reactivation
Third Party Viral Specific T-cells (VSTs)
The purpose of this study is to demonstrate that viral specific T-cells (a type of white blood cell) can be generated from an unrelated donor and given safely to patients with viral infections.
- Conditions
- Viral Infection, Viral Reactivation, Infection in an Immunocompromised Host
- Trial name
- NCT02532452
- Testing
- Viral Specific VST Infusion
- Where
- 4 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Respiratory Syncytial Virus (RSV)
Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons
This clinical trial is being done to learn more about how well a vaccine (Arexvy®) for respiratory syncytial virus, also known as RSV, works in people with weakened immune systems.
- Trial name
- STRIVE (NCT07050732)
- Testing
- Arexvy (2 doses total), Arexvy (3 doses total), Arexvy (1 dose total)
- Where
- United States
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Pneumocystis, Pneumocystis Infection
Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives)
The usual first treatment for Pneumocystis jirovecii pneumonia (PCP) is an antibiotic called trimethoprim-sulfamethoxazole (TMP-SMX).
- Conditions
- Pneumocystis, Pneumocystis Infection, Pneumocystis Carinii Infection, Pneumocystis Carinii; Infection, Resulting From HIV Disease
- Trial name
- SPIRIT-ALT (NCT07357103)
- Testing
- Clindamycin + primaquine, Pentamidine, Atovaquone
- Volunteers
- 416 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Breast Cancer, Triple Negative Breast Cancer
Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
This is a randomized, open-label phase III clinical trial comparing antivascular therapy combined with standard chemotherapy and standard chemotherapy in adjuvant therapy for patients with triple-negative breast cancer…
- Trial name
- NCT05909332
- Testing
- Antivascular therapy, Chemotherapy
- Where
- 15 sites in China
- Volunteers
- 764 people
- Sponsor
- Fudan University
Diarrhea
Safety of Lactobacillus LB Postbiotic in Immunocompromised Paediatric Patients With Diarrhoeal Disease
This prospective, interventional, single-center, open-label, phase 1 clinical trial to assess the safety of the Postbiotic Lactobacillus LB in immunocompromised paediatric patients with diarrhoeal disease will be performed at…
- Trial name
- NCT07758933
- Testing
- Lactobacillus LB
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- Hospital Infantil de Mexico Federico Gomez
Anogenital Herpes, COVID-19
Viral Infections in Healthy and Immunocompromised Hosts
Background: Viral infections are an important cause of illness and death in hospitalized patients as well as outpatients. New strains of viruses may appear and infect both healthy people and those with weak immune systems.
- Conditions
- Anogenital Herpes, COVID-19, Herpes Labialis
- Trial name
- NCT01306084
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Immunocompromised Patients
Immunogenicity, Efficacy and Safety of Recombinant Herpes Zoster Vaccine in Frail Patients
Herpes zoster (HZ) is a serious health problem whose incidence and severity increase with the decline of cell-mediated immunity (CMI) because of age and immunocompromised (IC) status.
- Trial name
- AID4FRAIL_RZV (NCT07321808)
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Critically-ill Patients
Immunosuppression and Intensive Care Unit-acquired Multidrug-resistant Bacteria
Antimicrobial resistance AMR is an emerging global threat to human health, and intensive care units (ICUs) are a 'hot spot' for the emergence and diffusion of multidrug-resistant (MDR) bacteria.
- Trial name
- TANGERINE (NCT06652126)
- Testing
- Microbiological examinations.
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- University Hospital, Lille
Hematopoietic and Lymphoid Cell Neoplasm, Immunocompromised
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
This phase I trial studies the side effects of allogeneic adenovirus-specific cytotoxic T lymphocytes (donor T cell therapy) and to see how well they work in treating patients with a weakened immune system (immunocompromised) and…
- Trial name
- NCT03425526
- Testing
- Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Pneumocystis Jiroveci Pneumonia
Corticosteroids for PJP in Non-HIV Immunocompromised Adults
Pneumocystis jirovecii pneumonia (PJP) is one of the common severe complications in immunocompromised patients, with a reported mortality rate of 60-80%.
- Trial name
- CAPSTONE-PJP (NCT07152613)
- Testing
- Saline (0.9%, sterile, for infusion), Low Dose Corticosteroids, Moderate dose corticosteroids
- Volunteers
- 240 people
- Sponsor
- Qingyuan Zhan